- Poster presentation
- Open Access
Effect of magnesium on prophylaxis of vasospasm, morbidity, and mortality in subarachnoid hemorrhage patients
Critical Care volume 13, Article number: P54 (2009)
We propose this study in order to reach two end points: (a) vasospasm clinical incidence, confirmed by CT; and (b) the mortality of these patients in 28 days. The study shows a comparison of a group of patients that used Mg (Intervention Group 1) from those that did not (Control Group 2).
After institutional approval and informed consent, a prospective, randomized, nonblind study was performed between February and November 2008. The main goal of the study was to achieve a Mg serum concentration from 2.5 to 3.5 mg/dl, using a solution of Mg 2% (SG 5% 400 ml + MgSO4 10% 100 ml/24 hours), during the first 14 days of aneurysm rupture. Admission criteria: patients diagnosed with SAH and Δt <96 hours. Exclusion criteria: patients with SAH and Δt >96 hours.
In a previous study evaluation we analysed a total of 56 patients, with 26 in Group 1 and 30 in Group 2 (Tables 1 and 2). Main results: Group 1 – vasospasm frequency 26.9% (n = 7) and mortality 19.2% (n = 5) in 28 days; Group 2 – vasospasm frequency 46.7% (n = 14) and mortality 33.3% (n = 10) in 28 days.
According to the outcome, we can conclude that Group 1 obtained a greater protection for vasospasm incidence and a decrease of mortality in comparison with Group 2. The P value was not significant due to a still small number of patients.
About this article
Cite this article
Macedo, S., Nuss, R., Pereira, S. et al. Effect of magnesium on prophylaxis of vasospasm, morbidity, and mortality in subarachnoid hemorrhage patients. Crit Care 13, P54 (2009). https://doi.org/10.1186/cc7856
- Intervention Group
- Informed Consent
- Exclusion Criterion
- Serum Concentration